Blood Flow Monitoring to Prevent Post-Polypectomy Induced Ulcer Bleeding
Status: | Recruiting |
---|---|
Conditions: | Gastrointestinal |
Therapuetic Areas: | Gastroenterology |
Healthy: | No |
Age Range: | 45 - Any |
Updated: | 4/3/2019 |
Start Date: | February 1, 2017 |
End Date: | January 31, 2022 |
Contact: | Dennis M Jensen, MD |
Email: | dennis.jensen@va.gov |
Phone: | (310) 268-3569 |
Blood Flow Monitoring to Prevent Post-Polypectomy Induced Ulcer Bleeding.
The primary specific aim is to perform a randomized controlled trial (RCT) to compare rates
of delayed hemorrhage after DEP detection of arterial blood flow and focal treatment in
PPIU's (treatment arm) with standard treatment using medical guidelines alone (controls) for
prevention of delayed bleeding in high risk patients (on anti-coagulants or anti-platelet
drugs or with large ulcers) after snare resection of benign colon polyps.
of delayed hemorrhage after DEP detection of arterial blood flow and focal treatment in
PPIU's (treatment arm) with standard treatment using medical guidelines alone (controls) for
prevention of delayed bleeding in high risk patients (on anti-coagulants or anti-platelet
drugs or with large ulcers) after snare resection of benign colon polyps.
Severe delayed post-polypectomy induced ulcer (PPIU) bleeding has become a much more common
problem with the increased numbers of colonoscopies being performed and with more patients
taking anti-coagulants or anti-platelet drugs. Current medical guidelines may reduce bleeding
during polypectomy, but are not effective for prevention of delayed bleeding. Empiric closure
of PPIU's with clips is not effective because ulcers > 15 mm cannot be closed, does not treat
the underlying artery in the ulcer base, and when the clips often fall off within 7 the
underlying artery is exposed. As preliminary results, the investigators studied delayed PPIU
bleeds and their prevention, used a Doppler endoscopic probe (DEP) to localize arteries in
PPIU's, reported the prevalence which rises significantly as ulcer size increases, and
successfully obliterated blood flow with focal treatment. These studies form the basis for
this new RCT. The primary specific aim is to perform a RCT to compare rates of delayed
hemorrhage after DEP detection of arterial blood flow and focal treatment in PPIU's
(treatment arm) with standard treatment using medical guidelines alone (controls) for
prevention of delayed bleeding in high risk patients (on anti-coagulants or anti-platelet
drugs or with large ulcers) after snare resection of benign colon polyps. Secondary specific
aims are to evaluate the natural history and risk factors for delayed PPIU bleeding using
univariate and multivariable analyses. This is a RCT performed by the CURE Hemostasis
Research Group for high risk patients - those with PPIU's 15 mm in size or greater but not on
drugs associated with bleeding; or patients who require anti-coagulants or anti-platelet
drugs for treatment of co-morbid conditions and have PPIU's 10 mm or larger. Outpatients,
scheduled for screening or surveillance colonoscopies, who give written informed consent and
meet entry criteria will be randomized to control/no DEP (medical treatment without PPIU
closure) or DEP (as a guide to arterial blood flow detection and focal obliteration of it
with hemoclips and/or low power multipolar electrocautery [MPEC] probe). Patients will be
prospectively followed at 7, 14, and 30 days for bleeding, complications, or unscheduled
visits for healthcare after polypectomies.
problem with the increased numbers of colonoscopies being performed and with more patients
taking anti-coagulants or anti-platelet drugs. Current medical guidelines may reduce bleeding
during polypectomy, but are not effective for prevention of delayed bleeding. Empiric closure
of PPIU's with clips is not effective because ulcers > 15 mm cannot be closed, does not treat
the underlying artery in the ulcer base, and when the clips often fall off within 7 the
underlying artery is exposed. As preliminary results, the investigators studied delayed PPIU
bleeds and their prevention, used a Doppler endoscopic probe (DEP) to localize arteries in
PPIU's, reported the prevalence which rises significantly as ulcer size increases, and
successfully obliterated blood flow with focal treatment. These studies form the basis for
this new RCT. The primary specific aim is to perform a RCT to compare rates of delayed
hemorrhage after DEP detection of arterial blood flow and focal treatment in PPIU's
(treatment arm) with standard treatment using medical guidelines alone (controls) for
prevention of delayed bleeding in high risk patients (on anti-coagulants or anti-platelet
drugs or with large ulcers) after snare resection of benign colon polyps. Secondary specific
aims are to evaluate the natural history and risk factors for delayed PPIU bleeding using
univariate and multivariable analyses. This is a RCT performed by the CURE Hemostasis
Research Group for high risk patients - those with PPIU's 15 mm in size or greater but not on
drugs associated with bleeding; or patients who require anti-coagulants or anti-platelet
drugs for treatment of co-morbid conditions and have PPIU's 10 mm or larger. Outpatients,
scheduled for screening or surveillance colonoscopies, who give written informed consent and
meet entry criteria will be randomized to control/no DEP (medical treatment without PPIU
closure) or DEP (as a guide to arterial blood flow detection and focal obliteration of it
with hemoclips and/or low power multipolar electrocautery [MPEC] probe). Patients will be
prospectively followed at 7, 14, and 30 days for bleeding, complications, or unscheduled
visits for healthcare after polypectomies.
Inclusion Criteria:
- Ambulatory patients, 45 years old or more and who are having:
- elective, outpatient screening
- surveillance colonoscopy for colon cancer or polyps
- or being evaluated for abdominal pain or change in bowel habits
- Clinically the patient has to have a medical indication and recommendation by their
primary care physician (PCP) or specialist to take:
- daily anti-coagulants (Warfarin, low-molecular-weight heparin [LMWH] or a newer
agent)
- or an anti-platelet drug (aspirin as 81 mg or more, Clopidogrel, or newer agents)
for PPIU's 10-14mm
- or if not on one of these drugs, they must have a PPIU 15 mm
- On colonoscopy, they are required to have:
- benign appearing polyps and for 1 or more PPIU to be 10 mm in size (for the
anti-coagulant or anti-platelet groups)
- or 15 mm or larger for the PPIU group who do not have to be (but may be) on these
drugs that can induce bleeding
- In the case of bleeding from the PPIU during polypectomy, hemorrhage must be
completely controlled
Exclusion Criteria:
- Inability or unwillingness to give written informed consent or to return to the
investigators' medical centers for follow-up (FU) in the next 30 days, in case of
delayed bleeding or other complications
- Intrinsic bleeding disorder with a history of recurrent bleeding either after:
- surgeries
- angiography
- or other invasive procedures
- Significantly abnormal coagulation tests related to co-morbid liver, hematologic, or
infectious disorders and not anti-coagulant drugs, with platelet count < 100,000;
international normalized ratio (INR) > 1.5; or partial thromboplastin time (PTT) more
than 1.5 times normal
- Inflammatory bowel disease
- Infectious colitis
- Idiopathic colitis with a history of recurrent rectal bleeding
- Recurrent rectal bleeding from another chronic colorectal condition such as:
- colonic angiomas
- radiation colitis
- proctitis
- or internal hemorrhoids
- A sessile polyp that can not be raised up by saline injection or Endoscopic mucosal
resection (EMR) techniques nor completely removed by snare polypectomy either en block
or in pieces and there is a suspicion about possible malignancy by the colonoscopist.
- Recently colonoscopy (within less than 3 years) unless the patient is referred for a
large or multiple polyps (on more recent colonoscopy) and colonoscopic removal in the
investigators' referral centers
We found this trial at
3
sites
9333 Imperial Highway
Downey, California 90242
Downey, California 90242
Phone: 562-657-4441
Click here to add this to my saved trials
Los Angeles, California 90095
Phone: 310-268-3569
Click here to add this to my saved trials
West Los Angeles, California 90073
Principal Investigator: Dennis M. Jensen, MD
Phone: 310-268-3569
Click here to add this to my saved trials